Subscribe
ugisrigba
Ugis Rigba / Shutterstock.com
28 May 2020Big PharmaRory O'Neill

Report slams big pharma influence in EU-funded project

A  new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative (IMI) as favouring Big Pharma over small businesses, particularly when it comes to IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More features

Three reasons why the UK should reconsider joining the UPC
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies
USPTO’s Stewart: Don’t nix patents as penalty for misconduct
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam
‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal
Wilson Sonsini adds veteran USPTO examiner as senior patent counsel
Make your voice heard: Call for input on AI, the UPC, and patent trends
J&J unit could owe biotech $125m over AI-based surgical ‘night vision’ tech